Pratt C B, Luo X, Fang L, Marina N, Avery L, Furman W L
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318, USA.
Med Pediatr Oncol. 1996 Sep;27(3):145-8. doi: 10.1002/(SICI)1096-911X(199609)27:3<145::AID-MPO2>3.0.CO;2-E.
One hundred thirty-eight pediatric patients have received treatment for malignant solid tumors with ifosfamide with mesna, and 71 have received a combination with ifosfamide/carboplatin/etoposide (ICE). Responses were obtained in many types of pediatric tumors, yet comparison of responses was not possible because of inadequate numbers of tumors of differing histiotypes. Comparison of results between patients with all tumors treated with ifosfamide or ICE indicated that there was a higher response rate for patients treated with ICE, with an estimated odds ratio of 2.74 (95% C.I. 1.45-5.179). Excluding patients without prior chemotherapy and radiotherapy, the odds ratio for 2.801 (95% C.I. 1.45-5.4) suggests a similar result. There remain no guarantees that the more costly treatment with ICE, which requires cytokine support, will offer therapeutic benefits against resistant solid tumors.
138名儿科患者接受了异环磷酰胺联合美司钠治疗恶性实体瘤，71名患者接受了异环磷酰胺/卡铂/依托泊苷（ICE）联合治疗。多种儿科肿瘤均有反应，但由于不同组织学类型的肿瘤数量不足，无法进行反应比较。对所有接受异环磷酰胺或ICE治疗的肿瘤患者的结果进行比较表明，接受ICE治疗的患者缓解率更高，估计优势比为2.74（95%置信区间1.45 - 5.179）。排除未接受过化疗和放疗的患者，优势比为2.801（95%置信区间1.45 - 5.4），结果相似。仍然不能保证需要细胞因子支持的更昂贵的ICE治疗对耐药实体瘤有治疗益处。
